1. Home
  2. HLNE vs KYMR Comparison

HLNE vs KYMR Comparison

Compare HLNE & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

HOLD

Current Price

$128.43

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

HOLD

Current Price

$85.47

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLNE
KYMR
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.7B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
HLNE
KYMR
Price
$128.43
$85.47
Analyst Decision
Buy
Strong Buy
Analyst Count
9
23
Target Price
$160.56
$101.43
AVG Volume (30 Days)
505.9K
1.4M
Earning Date
02-03-2026
11-04-2025
Dividend Yield
1.66%
N/A
EPS Growth
19.80
N/A
EPS
5.55
N/A
Revenue
$733,070,000.00
$43,735,000.00
Revenue This Year
$8.42
$20.81
Revenue Next Year
$19.65
N/A
P/E Ratio
$23.48
N/A
Revenue Growth
13.01
N/A
52 Week Low
$111.98
$19.45
52 Week High
$179.19
$103.00

Technical Indicators

Market Signals
Indicator
HLNE
KYMR
Relative Strength Index (RSI) 54.23 65.77
Support Level $121.55 $86.23
Resistance Level $135.56 $93.82
Average True Range (ATR) 4.25 4.75
MACD 0.84 1.86
Stochastic Oscillator 56.94 55.41

Price Performance

Historical Comparison
HLNE
KYMR

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Share on Social Networks: